B-type natriuretic peptide plasma level in 5-year breast cancer survivors after radiotherapy

Portaluri, Maurizio; Petruzzelli, Maria Fonte; Tramacere, Francesco; Andreassi, Maria Grazia

doi:10.1080/09553002.2019.1542183

Cited by 7 publications

(10 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, a long-term retrospective study reported that median plasma BNP levels in 5-year breast cancer survivors after radiation therapy remain within the normal range, but the delta-BNP levels are positively related to the mean heart dose and mean left ventricular dose received. 24 However, the significance of BNP in the diagnosis and evaluation of radiation-induced cardiac disease is not fully understood. Our results showed that BNP had not changed after RT, compared with BNP at the baseline, indicating BNP would not increase in short-term post-radiation therapy.…”

Section: Discussionmentioning

confidence: 99%

“…In the small sample longitudinal study of cardiac biomarkers in patients receiving thoracic radiotherapy, Gomez et al showed that BNP increases during high‐dose irradiation of the heart in some patients. Recently, a long‐term retrospective study reported that median plasma BNP levels in 5‐year breast cancer survivors after radiation therapy remain within the normal range, but the delta‐BNP levels are positively related to the mean heart dose and mean left ventricular dose received …”

Section: Discussionmentioning

confidence: 99%

“…Accumulated results from clinical studies have shown that high cardiac radiation dose is directly associated with RIHDs. 24,[27][28][29] Oncologists must also consider the rate of cancer control and the dose of cardiac radiation when formulating a RT regimen. In childhood cancer survivors, a large sample case control study revealed that heart failure often occurred in patients that received ≥30 Gy to the median volume of the heart.…”

Section: Ta B L E 2 Relationship Between Heart Dose Parameters and Stmentioning

confidence: 99%

See 2 more Smart Citations

Positive association between heart dosimetry parameters and a novel cardiac biomarker, solubleST‐2, in thoracic cancer chest radiation

Zeng

Zhou

et al. 2020

Clinical Laboratory Analysis

View full text Add to dashboard Cite

Abbreviations: BNP, B-type natriuretic peptide; DVH, dose-volume histogram; IMRT, intensity-modulated radiotherapy; IQR, interquartile range; LVEF, the left ventricle ejection fraction; MHD, mean heart dose; M-LAD, mean dose of left anterior descending artery; RIHD, radiation-induced heart disease; RT, radiotherapy; sST-2, solubleST-2; VMRT, volumetric-modulated radiotherapy. AbstractBackground: Early screening and diagnosis of radiation-induced heart disease (RIHD)is difficult in patients with chest radiation exposure. sST-2 is involved in myocardial stress or injury. We evaluated the relationship between heart dose parameters and sST-2 changes in chest malignant tumor patients who received chest radiation. Methods:We prospectively collected thoracic malignancy cancer patients who had received chest radiotherapy. Heart dosimetry parameters were extracted from the treatment planning system. sST-2 was measured at baseline, the middle stage, and after radiotherapy (recorded as pre-ST-2, mid-ST-2, and post-ST-2). sST-2 change rate was calculated. Scatter plots showed the relationship between cardiac dose parameters and ST-2 change rate. Multiple regression was used to analyze the relationship between cardiac dose parameters and ST-2 change rate. Results:Totally, 60 patients were enrolled. The mean V 5 , V 10 , V 20 , V 30 , V 40 , and MHD was 60.93 ± 27.79%, 51.43 ± 25.44%, 39.17 ± 21.75%, 28.07 ± 17.15%,18.66 ± 12.18%, and 18.60 ± 8.63 Gy, respectively. The median M-LAD was 11.31 (IQR 3.33-18.76) Gy. The mean pre-ST-2, mid-ST-2, and post-ST-2 was 5.1 ± 3.8, 6.4 ± 3.9, and 7.6 ± 4.4, respectively. sST-2 was elevated with thoracic irradiation (P < .001). Multivariate linear regression analyses showed that V 5 , V 10 , V 20 , and MHD were independently and positively associated with ST-2 change rate (β = .04, .04, .04, and .10, respectively, all P < .05). Conclusion: Serum sST-2 levels were elevated over time during radiotherapy. V 5 , V 10 , V 20 and MHD were independently and positively associated with the elevated ST-2 change rate. K E Y W O R D S cardiac biomarker, heart dosimetry parameters, radiation-induced heart disease, radiotherapy, sST-2 S U PP O RTI N G I N FO R M ATI O N Additional supporting information may be found online in the Supporting Information section. How to cite this article: Zeng Z-M, Xu P, Zhou S, et al. Positive association between heart dosimetry parameters and a novel cardiac biomarker, solubleST-2, in thoracic cancer chest radiation. J Clin Lab Anal. 2020;34:e23150. https ://doi.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Ta B L E 2 Relationship Between Heart Dose Parameters and Stmentioning

confidence: 99%

See 1 more Smart Citation

Positive association between heart dosimetry parameters and a novel cardiac biomarker, solubleST‐2, in thoracic cancer chest radiation

Zeng

Zhou

et al. 2020

Clinical Laboratory Analysis

View full text Add to dashboard Cite

show abstract

“…In the small sample longitudinal study of cardiac Biomarkers in patients receiving thoracic radiotherapy, Gomez et al [19] showed that BNP increased during high doses of radiation to the heart in some patients. Recently, a long term retrospective study reported that median plasma BNP levels in 5-year breast cancer survivors after radiation therapy remained within the normal range, but the delta-BNP levels are positively related to the mean heart dose and mean left ventricular dose received [20].…”

Section: Discussionmentioning

confidence: 99%

“…Accumulated results from clinical studies have shown that high cardiac radiation dose is directly associated with radiation-induced heart diseases [20,[23][24][25]. When make the radiotherapy regiment, oncologists must also consider tumor control rate and meanwhile the cardiac exposure dose.…”

Section: Discussionmentioning

confidence: 99%

Positively association between novel cardiac biomarkers soluble ST2 and heart Dosimetry parameter in thoracic cancer chest radiation

Zeng

Zhou

et al. 2019

Preprint

View full text Add to dashboard Cite

Background Early screening and diagnosis of radiation-induced heart disease are difficult in patients with chest radiation exposure. sST2 involved in myocardial stress or injury. We aimed to evaluate short-term sST2, B-type natriuretic peptide (BNP) and the left ventricle ejection fraction (LVEF) changes and the relationship between sST2 and heart dose in patients who receive chest radiation. Methods We prospectively collected thoracic malignancy cancer patients from October 2016 to August 2018 who received chest radiotherapy. sST2 and BNP was measured before (recorded as preST2, preBNP), in the middle (recorded as midST2, midBNP) and after radiotherapy (recorded as postST2, postBNP). LVEF was detected using echocardiography before and after radiotherapy. BNP and sST2 among pre, mid, post groups were compared using nonparametric test. LVEF was compared using pair t-test. Standardized sST2 was calculated as postsST2/presST2. The correlation of standardized sST2 and heart dosimetry parameters were measured by Spearman’s correlation test. Results Sixty patients were enrolled, including 37(61.67%) lung cancer, 18(30.00%) esophageal cancer and 5 (8.33%) thymoma patients. The median preST2, midST2, postST2 was 3.86 (IQR1.56-8.37), 6.33 (IQR 2.01-9.32) and 8.00 (IQR 4.2- 10.9) respectively. sST2 elevated with the progression of thoracic irradiation (p<0.001). The median preBNP, midBNP and postBNP was 22.56 (IQR 7.25-63.5), 32.25 (IQR 18.85-52.97) and 32.41 (IQR 17.23-55.97), respectively. The mean preLVEF and postLVEF was 64.36 and 62.76, respectively. There was no significant change in BNP and LVEF after radiotherapy. Standardized sST2 was correlation with V5Gy, V10Gy, V20Gy, V30Gy, mean heart dose and left anterior descending artery (LAD) (V5Gy rs = 0.541, p = 0.00; V10Gy rs = 0.504, p = 0.00; V20Gy rs = 0.437, p = 0.001; V30Gy, rs = 0.305, p = 0.026; mean heart dose rs = 0.395, p = 0.003 and mean heart dose of LAD rs = 0.414, p = 0.002). Conclusion BNP and LVEF were not changed after thoracic radiation. Serum sST2 levels were elevated during radiotherapy and associated with heart dose parameters in thoracic malignant tumor patients. sST2 would be regarded as a potential early diagnostic marker for RIHD.

show abstract

Research progress of cardiotoxicity caused by radiotherapy in breast cancer

Xu,

Yin,

Zhang

et al. 2024

Precision Radiation Oncology

View full text Add to dashboard Cite

Breast cancer has surpassed lung cancer as the most common type of malignancy worldwide. Treatments for breast cancer include surgery, chemotherapy, radiotherapy, targeted therapy, endocrine therapy, immunotherapy, and hyperthermia. Radiotherapy plays an important role in breast cancer treatment. Patients with early breast cancer can have longer survival after combined treatment, but cardiotoxicity caused by radiotherapy may affect long‐term prognosis. This article reviews cardiac damage caused by radiotherapy in breast cancer.

show abstract

B-type natriuretic peptide plasma level in 5-year breast cancer survivors after radiotherapy

Cited by 7 publications

References 32 publications

Positive association between heart dosimetry parameters and a novel cardiac biomarker, solubleST‐2, in thoracic cancer chest radiation

Positive association between heart dosimetry parameters and a novel cardiac biomarker, solubleST‐2, in thoracic cancer chest radiation

Positively association between novel cardiac biomarkers soluble ST2 and heart Dosimetry parameter in thoracic cancer chest radiation

Research progress of cardiotoxicity caused by radiotherapy in breast cancer

Contact Info

Product

Resources

About